Introduction to Amphetamine Drug
Amphetamine (alpha-methylphenethylamine) is a central nervous system (CNS) stimulant that affects the nervous system of the body targeting brain chemicals for hyperactivity and impulse control. This drug is used to treat patients suffering from attention deficit hyperactivity disorder (ADHD), narcolepsy, and obesity among others. Amphetamine exists as two optically active forms or enantiomers: l-amphetamine (levo) and d-amphetamine (dextro). The first amphetamine medication was under the name of Benzedrine, a brand that was used to treat children with severe behavioral problems. Currently, medicinal amphetamine is prescribed under the brand names Adderall, Adderall XR, Mydayis, Evekeo, Evekeo ODT, and others. Improper dosage of amphetamine can cause death or serious side effects on the heart, which, in order to avoid, one must follow all medication guides that are given on prescription or instruction sheets. Additionally, one should not use the medication in larger or smaller amounts or for longer than recommended.
Market Size and Forecast
The global amphetamine drug market is expected to expand at a significant CAGR during the forecast period i.e., 2020-2028. The amphetamine drug market is segmented by application, by demography, by distribution channel, and by region. Based on the application, the amphetamine drug market is segmented into ADHD, narcolepsy, obesity, depression, and others. Out of these, the depression segment is anticipated to dominate the market owing to the increase in the prevalence of depression among adults and children around the world. On the basis of demographics, the amphetamine drug market has been bifurcated into children and adults. Among the demographic segment, the adult segment is anticipated to hold the largest share in the market which can be attributed to a large adult patient population. The amphetamine drug market is thriving on the back of increased research and development activities with the simultaneous approval of drugs. Additionally, the surge in central nervous system disorders, sleeping disorders, and depression cases along with a shift in consumer awareness regarding mental health is also expected to play a crucial role in driving the market growth. The rising number of people suffering from various disorders has caught the attention of governments around the world, forcing them to support the ADHD drug market to address this condition. Government approvals and commercialization of drugs by market players are some of the major factors that are anticipated to drive the growth of the market during the forecast period.
Presently, during COVID-19 pandemic individuals with attention-deficit hyperactivity disorder are facing difficulties, due to their vulnerability to the suffering caused by the pandemic and physical distancing methods. As a result of this current course of action, individuals with ADHD might display increased behavioral problems. On the back of this, the amphetamine drug market is estimated to witness significant growth.
Growth Drivers
The rising number of ADHD patients globally
According to the survey done by the Centers for Disease Control and Prevention (CDC) in 2016, 0.388 million children aged 2–5 years, 4 million children aged 6–11 years, and 3 million children aged 12–17 years were diagnosed with ADHD in the United States.
Rising incidences of ADHD across the globe can be attributed to the low threshold of diagnostic criteria. The number of ADHD patients is rising at an alarming rate, as there is no established treatment for this disorder except for long medication procedures. Pharmacological treatments through CNS stimulants such as amphetamine are the most appropriate way to treat ADHD patients. Such factors are expected to fuel revenue growth of the global amphetamine drug market.
Continuous Innovation by ADHD drug manufacturers
Market key players are continuously focusing on both, ADHD children and adults. For children, drugs are being manufactured with innovative ideas such as introducing fruit-flavors pills for easy consumption, while for adults, the focus is on reducing their daily dose by providing those doses with long-lasting effects. The packaging is another area of innovation, where blister packs are introduced instead of bottles to facilitate quick and convenient use. Manufacturers are also focusing on offering products, comparatively at lower costs. This factor is anticipated to increase the demand for amphetamine drugs in the coming years.
Restraints
Adverse effects associated with amphetamine drugs
Amphetamine generally involves larger and longer doses, which can develop some greater risk to the quality of a patient’s life. There are physical and psychological effects of this drug. The physical effects consist of cardiovascular side effects, gastrointestinal side effects, and other physical side effects such as blurred vision, nose bleeding, dry mouth, and others. Whereas, psychological side effects contain apprehension, mood swings, insomnia, wakefulness, and others. A large number of contraindications and side-effects associated with amphetamine drugs are limiting prescriptions based on the therapeutic condition of patients. Despite all the advantages, contraindications and side-effects associated with amphetamine drugs are hampering the life of patients, which is estimated to restrict the growth of the amphetamine drugs market over the forecast period.
Market Segmentation
In-depth analysis of the global amphetamine drug market includes the following segments:
By Application Type:
- ADHD
- Narcolepsy
- Obesity
- Depression
- Others
By Demography Type:
- Adult
- Children
By Distribution Channel Type:
- Retail Pharmacy
- Hospital Pharmacy
By Region Type
On the basis of regional analysis, the global amphetamine drug market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa region.
Based on the region, the market in North America is anticipated to dominate the global market and account for prevalence in the higher number of depression and ADHD patients. Thus, a large volume of drug is being prescribed every year. Additionally, collaborations among market key players to increase market penetration for product development and effortless commercialization of the product. Such factors are anticipated to boost the market growth of the region are estimated to bring in more revenues in the market. The second-largest market share is anticipated to be held by the market in Europe owing to the presence of massive pharmaceutical companies along with increasing awareness about mental health in the region. The market in Asia Pacific region is expected to expand at a higher rate during the forecast period owing to the upsurge in the demand for drugs for the treatment of various disorders problems such as ADHD.
The global amphetamine drug market is further classified on the basis of region as follows:
- North America (U.S. & Canada) Market size, Y-O-Y growth & Opportunity Analysis
- Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Opportunity Analysis
- Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC, Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth & Opportunity Analysis
- Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Opportunity Analysis
- The Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of the Middle East and Africa) Market size, Y-O-Y growth & Opportunity Analysis
Top Featured Companies Dominating the Market
- Teva Pharmaceutical Industries Ltd.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Pfizer Inc.
- Novartis AG
- Eli Lilly and Company
- GlaxoSmithKline plc
- Mallinckrodt Company
- Johnson & Johnson Services, Inc.
- Hisamitsu Pharmaceutical Co., Inc.
- Purdue Pharma L.P.
